Patient’s Desire and Real Availability Concerning Supportive Measures Accompanying Radical Prostatectomy: Differences between Certified Prostate Cancer Centers and Non-Certified Centers Based on Patient-Reported Outcomes within the Cross-Sectional Study ImproveIngmar Wolff, Matthias May, Martin Burchardt et al.|Cancers|2023Cited by 11
Patients Regret Their Choice of Therapy Significantly Less Frequently after Robot-Assisted Radical Prostatectomy as Opposed to Open Radical Prostatectomy: Patient-Reported Results of the Multicenter Cross-Sectional IMPROVE StudyIngmar Wolff, Matthias May, J. Peter et al.|Cancers|2022Cited by 10
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patientsAlexander Scheiter, Kirsten Utpatel, Simon Mellin et al.|BMC Medicine|2026Cited by 2
Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combinationC. Aydogdu, Jozefina Casuscelli, Pia Paffenholz et al.|European Urology|2024Cited by 0
Impact of patients' health insurance status on the type of radical prostatectomy for localized prostate cancer in Germany: An observational analysis based on the multicentric IMPROVE studyMatthias May, Ingmar Wolff, Christian Gilfrich et al.|Journal of Surgical Oncology|2023Cited by 0